An HLA-B genetic test identifies inherited alleles at the HLA-B locus, one of the most variable immune-system genes in humans. The same gene can be tested for very different reasons. Transplant laboratories use high-resolution HLA-B typing to compare donors and recipients. Prescribers may order a targeted allele such as HLA-B57:01, HLA-B58:01, or HLA-B*15:02 before a specific medicine. Rheumatology and other specialties may use HLA-B27 or HLA-B51 as supporting disease-risk markers. These results are not interchangeable. A report that says “HLA-B27 positive” does not provide the full HLA-B genotype, and broad HLA-B typing may not be validated for a medication decision unless it resolves the exact allele. HLA-B alleles are normal inherited variants rather than harmful mutations. Their meaning comes from context: an allele may be a donor mismatch, a target of an HLA antibody, a pharmacogenetic risk factor, or a disease association. A valid germline result generally remains the same for life.
- HLA-B testing identifies inherited immune alleles; it does not measure inflammation or antibody levels.
- Transplant use usually requires both HLA-B alleles at high resolution, not a single positive/negative marker.
- Drug-safety results are allele-specific: HLA-B*57:01, *58:01, and *15:02 have different medication implications.
- HLA-B27 or HLA-B51 can support a clinical evaluation but cannot diagnose disease alone.
- After donor stem-cell transplantation, blood may show the donor’s HLA-B type rather than the recipient’s original type.
Table of Contents
- What HLA-B Is
- Why an HLA-B Test Is Ordered
- Testing Methods and Sample Requirements
- How to Read HLA-B Results
- HLA-B in Transplant Compatibility
- HLA-B and Drug Reaction Risk
- HLA-B27, HLA-B51, and Other Disease Associations
- Limitations and Next Steps
What HLA-B Is
HLA-B is a classical class I human leukocyte antigen gene in the major histocompatibility complex on chromosome 6. It encodes the heavy chain of an HLA-B molecule. On the cell surface, that chain pairs with beta-2 microglobulin and holds a short peptide in a binding groove.
Most nucleated cells display HLA-B. CD8 T cells inspect the peptide-HLA complex. Peptides from normal proteins usually signal “self,” while viral or altered cellular peptides can trigger an immune response. Natural killer cells also respond to HLA class I signals through killer-cell immunoglobulin-like receptors, or KIRs.
HLA-B is extraordinarily polymorphic. Thousands of named alleles differ in DNA sequence, protein structure, expression, or both. Variation is concentrated around the peptide-binding groove, allowing different HLA-B molecules to present different peptide sets. This diversity helps populations respond to many infections, but it also creates transplant incompatibility and allele-specific drug reactions.
Each person normally inherits one HLA-B allele from each biological parent. A high-resolution result may show HLA-B07:02 and HLA-B44:03. The person is heterozygous because the alleles differ. If both inherited copies are the same, the person is homozygous at HLA-B.
HLA genes sit close together and are commonly inherited as haplotypes. An HLA-B allele may therefore travel with particular HLA-A, HLA-C, or class II alleles in a population. This linkage can complicate disease-association studies because a signal attributed to HLA-B may partly reflect a nearby variant.
The word “positive” has no universal meaning for HLA-B. Everyone normally has HLA-B. A targeted test is positive when it detects the named allele. A transplant report instead lists two alleles, and compatibility is determined by comparing people. An HLA antibody test is different again: it measures acquired antibodies against HLA targets rather than inherited alleles.
Why an HLA-B Test Is Ordered
The clinical purpose determines which result is needed. Ordering “HLA-B” without stating the question can lead to the wrong method or resolution.
Solid-organ transplantation
Kidney, pancreas, heart, lung, and other transplant programs type donor and recipient HLA-B. The result contributes to compatibility assessment and helps determine whether recipient antibodies are directed against donor HLA-B antigens or alleles.
A traditional kidney mismatch count may use broad HLA-A, HLA-B, and HLA-DR antigens. Modern laboratories can add allele-level or epitope-level information. HLA-B compatibility is one factor among organ quality, donor age, waiting time, antibody status, and crossmatch findings.
Hematopoietic stem-cell transplantation
High-resolution HLA-B matching is a core part of unrelated donor selection. Common match schemes compare both alleles at HLA-A, HLA-B, HLA-C, and HLA-DRB1, with additional loci considered by program and transplant strategy.
HLA-B also contains a leader peptide dimorphism often described as methionine or threonine at position −21. This feature can influence interactions between HLA-E, natural killer cells, and T cells. Leader matching and HLA-B expression are active areas of donor-selection refinement, but they do not replace standard allele matching.
Medication safety
Targeted HLA-B testing can prevent specific severe drug reactions. Common examples include:
- HLA-B*57:01 before abacavir
- HLA-B*58:01 before allopurinol in populations or patients covered by prescribing guidance
- HLA-B*15:02 before carbamazepine or oxcarbazepine in relevant ancestry groups
- Other HLA-B alleles for selected medicines in regional guidelines or specialist practice
Each pair is a separate gene-drug interaction. A negative HLA-B57:01 test says nothing about HLA-B58:01 unless both were tested.
Inflammatory disease evaluation
HLA-B27 can support evaluation for axial spondyloarthritis, reactive arthritis, or related conditions. HLA-B51 is associated with Behçet disease. These tests modify probability and must be interpreted with symptoms and examination.
Platelet support and immune therapies
HLA-B typing can help select compatible platelets for a patient with HLA alloantibodies and transfusion refractoriness. Some peptide vaccines, T-cell receptor therapies, and immune assays also require a defined HLA-B allele because the target peptide is presented only by that molecule.
Research, ancestry analysis, and population registries are additional uses, but a research result may not meet clinical validation standards.
Testing Methods and Sample Requirements
Testing usually uses blood or a cheek swab. No fasting is needed. DNA is extracted and analyzed by a method chosen for the clinical question.
Serologic typing uses antibody reactions on lymphocytes to identify broad antigens such as B7, B8, B27, B44, B51, or B57. It remains useful in some settings but cannot distinguish many alleles within an antigen group.
Molecular methods include:
- Sequence-specific primer PCR, which amplifies selected allele groups or targeted alleles
- Sequence-specific oligonucleotide probes, which detect defined sequence motifs
- Real-time or allele-specific PCR for rapid pharmacogenetic screening
- Sanger sequence-based typing of important exons
- Next-generation sequencing across multiple HLA loci
- Long-read sequencing, which can phase variants across larger regions
A targeted medication test may return only “detected” or “not detected.” Transplant typing usually reports both alleles. High-resolution typing commonly identifies the protein-level allele, such as HLA-B*44:02. Additional fields can distinguish synonymous coding or noncoding differences.
HLA-B is difficult to type because of extreme sequence diversity and similarities across class I genes. Limited assays can produce ambiguity, meaning several allele combinations fit the observed pattern. Laboratories may resolve ambiguity with additional sequencing, family typing, or an independent method.
The specimen source needs special attention after an allogeneic stem-cell transplant. Blood cells are donor-derived, so blood typing can correctly show the donor HLA-B genotype. That may be useful for current immune-cell questions but wrong for the recipient’s inherited drug-risk status. Cheek swabs can contain enough donor white cells to create the same problem. The laboratory may request pretransplant material, hair follicles, or cultured skin cells.
Tumor samples can also mislead. Cancers may lose one HLA haplotype or alter HLA expression as an immune-evasion strategy. Tumor sequencing should not replace germline testing for transplant compatibility or pharmacogenetic prescribing.
Turnaround time can range from hours for urgent deceased-donor typing to several weeks for specialized sequencing. A confirmatory sample is often obtained before a living donor procedure or stem-cell collection, even when registry or screening data already exist.
How to Read HLA-B Results
HLA nomenclature looks technical because it records increasing levels of sequence detail. In HLA-B*57:01:
- HLA-B is the gene
- The asterisk separates the gene from the allele name
- 57 is the allele group, historically related to a serologic family
- 01 identifies a specific protein sequence within that group
A result of HLA-B57 is broader than HLA-B57:01. The B57 antigen group includes more than one allele. This distinction is essential because abacavir guidance applies to HLA-B57:01, not every possible B57 allele.
Common report patterns include:
Two-allele genotype
“HLA-B07:02, HLA-B44:03” means two different alleles were identified. In transplantation, both must be compared with the donor or recipient.
Homozygous genotype
“HLA-B*35:01 homozygous” means the same allele was detected on both inherited copies, or the assay found a pattern consistent with that genotype. Homozygosity is not inherently abnormal.
Target allele detected
“HLA-B*58:01 positive” normally means at least one copy is present. For most gene-drug guidance, a single copy is sufficient to classify the person as higher risk.
Target allele not detected
“HLA-B*58:01 negative” means that allele was not found by the assay. It does not mean HLA-B is absent; the person has other HLA-B alleles.
Ambiguous or low-resolution result
The report may list several possibilities or only an allele group. That may be adequate for one purpose and inadequate for another. Ask whether the ambiguity changes donor selection, antibody assignment, medication guidance, or therapy eligibility.
Suffixes can indicate expression. For example, an “N” suffix denotes a null allele that is not expressed as a normal surface protein. Low-expression or questionable-expression suffixes also exist. These details can matter in transplantation and immune therapy.
Do not label an HLA allele “pathogenic” simply because it raises risk. HLA-B27, HLA-B51, and medication-associated alleles are common functional variants. Their clinical interpretation differs from a disease-causing mutation in a single-gene disorder.
HLA-B in Transplant Compatibility
HLA-B is one of the most immunogenic HLA loci. A donor-recipient difference can be recognized by T cells or become a target for recipient antibodies. The effect depends on transplant type and the rest of the immune profile.
In kidney transplantation, a recipient can have zero, one, or two broad HLA-B mismatches. Better matching can improve long-term compatibility, especially for younger recipients who may need another transplant, but a perfect HLA-B match is not always worth a long wait or loss of a strong living donor.
Antibody specificity may be more immediately important. If a recipient has antibody against the donor’s HLA-B allele or a shared epitope on that allele, the antibody is donor-specific. A positive cell-based crossmatch can signal high immunologic risk. The crossmatch result, antibody strength, complement activity, history, and center protocol are reviewed together.
In unrelated donor stem-cell transplantation, both HLA-B alleles are usually matched at high resolution. A single mismatch can increase graft-versus-host disease, graft failure, or mortality risk, although the effect varies by the amino-acid difference, disease, conditioning, graft source, and GVHD-prevention approach.
A “10/10” or “12/12” match must be interpreted using the program’s locus definition. HLA-B may be fully matched even when another locus differs, or a donor may share a broad B antigen but differ at the allele level.
HLA-B molecules also interact with natural killer cell biology through KIR ligands, including Bw4 and Bw6 epitopes. Some programs consider HLA-B leader status, HLA-B expression, KIR relationships, or permissive mismatch models when several donors are otherwise similar. These refinements remain context-specific and should not be treated as universal rules.
A transplant decision should never rest on HLA-B alone. Donor age, CMV status, graft source, organ quality, urgency, HLA-DQ and other loci, preformed antibodies, and non-HLA clinical factors can outweigh a small HLA-B advantage.
HLA-B and Drug Reaction Risk
HLA pharmacogenetics is highly specific. A particular drug can bind directly or indirectly within an HLA molecule, alter the peptide repertoire, or promote recognition by drug-reactive T cells. The allele changes susceptibility, but exposure and other biological factors are still required.
HLA-B*57:01 and abacavir
HLA-B*57:01 strongly predicts abacavir hypersensitivity. Screening before treatment and avoiding abacavir in positive patients greatly reduces immunologically confirmed reactions. A negative result supports use but does not replace monitoring for other adverse effects. A person with a previous suspected abacavir hypersensitivity reaction should not be rechallenged solely because a later genetic test is negative.
HLA-B*58:01 and allopurinol
HLA-B*58:01 is associated with allopurinol-induced severe cutaneous adverse reactions, including SJS/TEN and DRESS. Testing recommendations depend on ancestry, local guidance, kidney disease, and clinical context. A positive result usually supports choosing another urate-lowering strategy. A negative result does not remove risks related to starting dose, kidney function, or other factors.
HLA-B*15:02 and carbamazepine
HLA-B15:02 is strongly associated with carbamazepine-induced SJS/TEN in several Asian populations. Testing is most useful before first exposure. HLA-A31:01 is a separate carbamazepine marker associated with a broader hypersensitivity spectrum. A negative result for one does not substitute for the other when both are relevant.
Other HLA-B drug associations exist, but strength and implementation vary by population and medicine. A panel may list research-level associations that are not covered by prescribing guidance. The clinician should confirm the exact drug, allele, phenotype, and recommendation rather than treating “HLA risk positive” as a general allergy result.
Genotype normally needs testing only once. The exact result should remain in the medication record. Avoid reducing it to “HLA-B positive,” which is meaningless without the allele.
HLA-B27, HLA-B51, and Other Disease Associations
HLA-B alleles influence which peptides are presented and how class I molecules interact with immune pathways. Some alleles are associated with disease susceptibility, protection, or severity, but most associations are probabilistic.
HLA-B27 is the best-known example. It is strongly associated with ankylosing spondylitis and the broader axial spondyloarthritis spectrum. Yet many healthy carriers never develop disease, and some patients with axial spondyloarthritis are negative. The test is useful when the clinical history already suggests inflammatory back pain, uveitis, psoriasis, inflammatory bowel disease, enthesitis, or a family history.
HLA-B51 is associated with Behçet disease, a multisystem inflammatory condition that can cause recurrent oral and genital ulcers, eye inflammation, skin lesions, vascular disease, neurologic disease, or gastrointestinal involvement. The allele is neither necessary nor sufficient for diagnosis and is common in some healthy populations.
Other HLA-B alleles have reported relationships with infections, autoimmune disease, cancer outcomes, and drug reactions. Population stratification and linked HLA haplotypes can create misleading associations, so research findings should not automatically become clinical tests.
Disease-marker results should be interpreted in absolute terms. An allele can multiply relative risk while most carriers remain healthy. Conversely, a negative result may only modestly lower probability when symptoms and imaging are strongly suggestive.
Targeted disease testing does not reveal the full immune state. HLA-B27 positivity cannot measure current spinal inflammation, and HLA-B51 positivity cannot show whether vasculitis is active. Examination, imaging, inflammatory markers, organ-specific tests, and longitudinal history provide that information.
Limitations and Next Steps
HLA-B testing is reliable when the method matches the question, but several errors in use are common:
- Treating a broad antigen as the same as an exact allele
- Assuming one targeted negative result covers all HLA-B risks
- Using research imputation as a clinical genotype
- Interpreting a disease association as a diagnosis
- Choosing a transplant donor from one locus alone
- Ignoring donor-derived DNA after stem-cell transplantation
- Copying an incomplete result into the medical record
Direct-to-consumer raw data usually contains selected markers rather than complete HLA-B sequencing. HLA imputation can be accurate in well-represented populations but less reliable in people whose ancestry is underrepresented in reference panels. Clinically actionable alleles should generally be confirmed with validated testing.
Ask the ordering clinician or laboratory:
- What exact clinical question was the test intended to answer?
- Were both HLA-B alleles typed or only one target allele screened?
- What resolution and method were used?
- Is the result adequate for transplantation, medication guidance, or disease assessment?
- Does any ambiguity or expression suffix change interpretation?
- Could the specimen reflect donor DNA or tumor-specific changes?
- Does the result require confirmation before action?
For transplantation, request the complete HLA profile, antibody interpretation, and crossmatch context. For medication safety, confirm the allele-drug pair and document the result permanently. For disease evaluation, combine the result with symptoms and objective findings rather than using it as a screening label.
A well-interpreted HLA-B test can prevent a severe drug reaction, refine donor selection, or support diagnosis. Its value comes from precision: the right allele, the right specimen, the right resolution, and the right clinical question.
HLA-B inheritance can also explain why relatives share some, but not all, clinically relevant alleles. A child receives one HLA haplotype from each parent. Full siblings have a one-in-four chance of inheriting the same two parental haplotypes, but a relative’s drug-risk result should not be copied into another person’s chart. Each individual needs their own validated result when a medication decision depends on it.
In antibody testing, HLA-B targets are often interpreted through shared epitopes rather than allele names alone. One antibody pattern may react with several B antigens that carry a common surface structure. This can make a person appear sensitized to donors they have never encountered and can explain why bead-test signals form groups. Histocompatibility laboratories use donor typing, epitope patterns, dilution studies, and cell-based crossmatches to decide whether the reactivity is clinically relevant.
HLA-B allele names are periodically extended as new sequence differences are discovered. A newer report may contain extra fields without representing a biologically different protein. Keeping the complete report allows a laboratory to translate older and newer nomenclature and determine whether the distinction affects expression, matching, or a medication guideline.
The timing of testing differs by use. Pharmacogenetic HLA-B testing should ideally be completed before the first dose, because it is preventive. Transplant typing may be repeated or confirmed as a donor search evolves, even though the genotype itself is unchanged, because a new specimen verifies identity and a newer method may provide higher resolution. Disease-associated testing is usually a one-time supportive test and should not be repeated during flares.
References
- HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation 2024 (Review)
- A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing 2024 (Review)
- HLA Genetics for the Human Diseases 2024 (Review)
- Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs 2024 (Guideline)
- Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation 2022
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Allopurinol Dosing Based on HLA-B Genotype: 2020 Update 2021 (Guideline)
Disclaimer
This article provides general information and cannot interpret an individual HLA-B result for transplantation, medication use, or disease diagnosis. A qualified clinician and, when appropriate, a histocompatibility or pharmacogenetics laboratory should review the exact allele, test resolution, specimen source, and clinical purpose. Do not change a donor plan or medication based on an incomplete or unconfirmed result.
